Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label NurOwn study in prodromal to mild Alzheimer's disease
NL-OMON49256Phase 2Withdrawn
- Sponsor
- BrainStorm Cell Therapeutics Inc.
- Start
- Jul 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MSC-NTF in Alzheimer's disease (AD), sponsored by BrainStorm Cell Therapeutics Inc. Primary endpoint: Safety and tolerability of repeated intrathecal NurOwn administration. Planned start Jul 2020; status: withdrawn.
02
Drugs
MSC-NTF
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON49256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49256.